[{"year":"2025","publication":"Molecular Therapy","language":[{"iso":"eng"}],"OA_type":"green","quality_controlled":"1","article_type":"original","date_published":"2025-10-04T00:00:00Z","date_created":"2025-12-28T23:01:26Z","citation":{"ieee":"R. Rica <i>et al.</i>, “Langerhans cell-targeted protein delivery enhances antigen-specific cellular immune response,” <i>Molecular Therapy</i>. Elsevier.","ista":"Rica R, Klein K, Johnson L, Carta G, Sarcevic M, Langer F, Rademacher C, Wawrzinek R, Quattrone F, Sparber F. Langerhans cell-targeted protein delivery enhances antigen-specific cellular immune response. Molecular Therapy.","ama":"Rica R, Klein K, Johnson L, et al. Langerhans cell-targeted protein delivery enhances antigen-specific cellular immune response. <i>Molecular Therapy</i>. doi:<a href=\"https://doi.org/10.1016/j.ymthe.2025.10.008\">10.1016/j.ymthe.2025.10.008</a>","apa":"Rica, R., Klein, K., Johnson, L., Carta, G., Sarcevic, M., Langer, F., … Sparber, F. (n.d.). Langerhans cell-targeted protein delivery enhances antigen-specific cellular immune response. <i>Molecular Therapy</i>. Elsevier. <a href=\"https://doi.org/10.1016/j.ymthe.2025.10.008\">https://doi.org/10.1016/j.ymthe.2025.10.008</a>","mla":"Rica, Ramona, et al. “Langerhans Cell-Targeted Protein Delivery Enhances Antigen-Specific Cellular Immune Response.” <i>Molecular Therapy</i>, Elsevier, doi:<a href=\"https://doi.org/10.1016/j.ymthe.2025.10.008\">10.1016/j.ymthe.2025.10.008</a>.","short":"R. Rica, K. Klein, L. Johnson, G. Carta, M. Sarcevic, F. Langer, C. Rademacher, R. Wawrzinek, F. Quattrone, F. Sparber, Molecular Therapy (n.d.).","chicago":"Rica, Ramona, Klara Klein, Litty Johnson, Gabriele Carta, Mirza Sarcevic, Freyja Langer, Christoph Rademacher, Robert Wawrzinek, Federica Quattrone, and Florian Sparber. “Langerhans Cell-Targeted Protein Delivery Enhances Antigen-Specific Cellular Immune Response.” <i>Molecular Therapy</i>. Elsevier, n.d. <a href=\"https://doi.org/10.1016/j.ymthe.2025.10.008\">https://doi.org/10.1016/j.ymthe.2025.10.008</a>."},"oa":1,"department":[{"_id":"PreCl"}],"oa_version":"Preprint","day":"04","article_processing_charge":"No","author":[{"full_name":"Rica, Ramona","first_name":"Ramona","last_name":"Rica"},{"last_name":"Klein","full_name":"Klein, Klara","first_name":"Klara"},{"last_name":"Johnson","first_name":"Litty","full_name":"Johnson, Litty"},{"full_name":"Carta, Gabriele","first_name":"Gabriele","last_name":"Carta"},{"last_name":"Sarcevic","first_name":"Mirza","full_name":"Sarcevic, Mirza"},{"full_name":"Langer, Freyja","first_name":"Freyja","id":"3C1BE782-F248-11E8-B48F-1D18A9856A87","last_name":"Langer"},{"full_name":"Rademacher, Christoph","first_name":"Christoph","last_name":"Rademacher"},{"full_name":"Wawrzinek, Robert","first_name":"Robert","last_name":"Wawrzinek"},{"last_name":"Quattrone","first_name":"Federica","full_name":"Quattrone, Federica"},{"full_name":"Sparber, Florian","first_name":"Florian","last_name":"Sparber"}],"user_id":"2DF688A6-F248-11E8-B48F-1D18A9856A87","month":"10","abstract":[{"lang":"eng","text":"Targeted antigen delivery to immune cells, particularly dendritic cells, has emerged as a promising strategy to enhance therapeutic efficacy of vaccines, while minimizing adverse effects associated with conventional immunization. In this study, we use our previously described small glycomimetic molecule that is selectively recognized by the Langerhans cell (LC)-specific surface receptor Langerin and demonstrate specific delivery of protein antigens to these specialized dendritic cells. Our results show that Langerin-mediated antigen delivery significantly enhances the immune response in vivo, resulting in increased expansion and activation of antigen-specific T cells, compared to immunization with unmodified antigen. We demonstrate the feasibility of our LC-targeted platform for immune cell-specific immunization with protein antigen and underscore the potential of LCs as an access point for next-generation vaccines and immunotherapies."}],"doi":"10.1016/j.ymthe.2025.10.008","type":"journal_article","acknowledgement":"This project was generously supported by Seedfinancing (grant no. P2282679) of the Austrian Bundesministerium für Digitalisierung und Wirtschaftsstandort and the Bundesministerium für Klimaschutz, Umwelt, Energie, Mobilität, Innovation, und Technologie, handled by the Austrian Wirtschaftsservice (aws), as well as by Life Science Call 2022 (grant no. FO999896442) of the Austrian Research Promotion Agency (FFG). We thank Mag. Michael Schunn from the PCF of the Institute of Science and Technology Austria for his continuous technical support.","publication_identifier":{"eissn":["1525-0024"],"issn":["1525-0016"]},"publication_status":"inpress","date_updated":"2025-12-29T09:55:05Z","_id":"20858","publisher":"Elsevier","OA_place":"repository","title":"Langerhans cell-targeted protein delivery enhances antigen-specific cellular immune response","scopus_import":"1","main_file_link":[{"open_access":"1","url":"https://doi.org/10.1101/2025.05.05.652195"}],"status":"public"},{"oa_version":"Published Version","oa":1,"department":[{"_id":"MaLo"}],"file":[{"date_created":"2020-03-03T10:55:13Z","date_updated":"2020-07-14T12:47:56Z","file_name":"2017_MolecularTherapy_Smole.pdf","content_type":"application/pdf","access_level":"open_access","file_size":3404806,"relation":"main_file","checksum":"ea8b1b28606dd1edab7379ba4fa3641f","creator":"dernst","file_id":"7561"}],"tmp":{"legal_code_url":"https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode","short":"CC BY-NC-ND (4.0)","name":"Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)","image":"/images/cc_by_nc_nd.png"},"author":[{"last_name":"Smole","full_name":"Smole, Anže","first_name":"Anže"},{"last_name":"Lainšček","full_name":"Lainšček, Duško","first_name":"Duško"},{"full_name":"Bezeljak, Urban","first_name":"Urban","id":"2A58201A-F248-11E8-B48F-1D18A9856A87","orcid":"0000-0003-1365-5631","last_name":"Bezeljak"},{"full_name":"Horvat, Simon","first_name":"Simon","last_name":"Horvat"},{"first_name":"Roman","full_name":"Jerala, Roman","last_name":"Jerala"}],"user_id":"317138e5-6ab7-11ef-aa6d-ffef3953e345","month":"01","license":"https://creativecommons.org/licenses/by-nc-nd/4.0/","issue":"1","isi":1,"article_processing_charge":"No","day":"01","language":[{"iso":"eng"}],"quality_controlled":"1","year":"2017","publication":"Molecular Therapy","article_type":"original","intvolume":"        25","ddc":["570"],"date_published":"2017-01-01T00:00:00Z","has_accepted_license":"1","citation":{"ieee":"A. Smole, D. Lainšček, U. Bezeljak, S. Horvat, and R. Jerala, “A synthetic mammalian therapeutic gene circuit for sensing and suppressing inflammation,” <i>Molecular Therapy</i>, vol. 25, no. 1. Elsevier, pp. 102–119, 2017.","ista":"Smole A, Lainšček D, Bezeljak U, Horvat S, Jerala R. 2017. A synthetic mammalian therapeutic gene circuit for sensing and suppressing inflammation. Molecular Therapy. 25(1), 102–119.","ama":"Smole A, Lainšček D, Bezeljak U, Horvat S, Jerala R. A synthetic mammalian therapeutic gene circuit for sensing and suppressing inflammation. <i>Molecular Therapy</i>. 2017;25(1):102-119. doi:<a href=\"https://doi.org/10.1016/j.ymthe.2016.10.005\">10.1016/j.ymthe.2016.10.005</a>","apa":"Smole, A., Lainšček, D., Bezeljak, U., Horvat, S., &#38; Jerala, R. (2017). A synthetic mammalian therapeutic gene circuit for sensing and suppressing inflammation. <i>Molecular Therapy</i>. Elsevier. <a href=\"https://doi.org/10.1016/j.ymthe.2016.10.005\">https://doi.org/10.1016/j.ymthe.2016.10.005</a>","mla":"Smole, Anže, et al. “A Synthetic Mammalian Therapeutic Gene Circuit for Sensing and Suppressing Inflammation.” <i>Molecular Therapy</i>, vol. 25, no. 1, Elsevier, 2017, pp. 102–19, doi:<a href=\"https://doi.org/10.1016/j.ymthe.2016.10.005\">10.1016/j.ymthe.2016.10.005</a>.","short":"A. Smole, D. Lainšček, U. Bezeljak, S. Horvat, R. Jerala, Molecular Therapy 25 (2017) 102–119.","chicago":"Smole, Anže, Duško Lainšček, Urban Bezeljak, Simon Horvat, and Roman Jerala. “A Synthetic Mammalian Therapeutic Gene Circuit for Sensing and Suppressing Inflammation.” <i>Molecular Therapy</i>. Elsevier, 2017. <a href=\"https://doi.org/10.1016/j.ymthe.2016.10.005\">https://doi.org/10.1016/j.ymthe.2016.10.005</a>."},"date_created":"2020-01-25T15:55:39Z","external_id":{"pmid":["28129106"],"isi":["000391901600013"]},"_id":"7360","page":"102-119","publisher":"Elsevier","title":"A synthetic mammalian therapeutic gene circuit for sensing and suppressing inflammation","status":"public","abstract":[{"text":"Inflammation, which is a highly regulated host response against danger signals, may be harmful if it is excessive and deregulated. Ideally, anti-inflammatory therapy should autonomously commence as soon as possible after the onset of inflammation, should be controllable by a physician, and should not systemically block beneficial immune response in the long term. We describe a genetically encoded anti-inflammatory mammalian cell device based on a modular engineered genetic circuit comprising a sensor, an amplifier, a “thresholder” to restrict activation of a positive-feedback loop, a combination of advanced clinically used biopharmaceutical proteins, and orthogonal regulatory elements that linked modules into the functional device. This genetic circuit was autonomously activated by inflammatory signals, including endogenous cecal ligation and puncture (CLP)-induced inflammation in mice and serum from a systemic juvenile idiopathic arthritis (sIJA) patient, and could be reset externally by a chemical signal. The microencapsulated anti-inflammatory device significantly reduced the pathology in dextran sodium sulfate (DSS)-induced acute murine colitis, demonstrating a synthetic immunological approach for autonomous anti-inflammatory therapy.","lang":"eng"}],"doi":"10.1016/j.ymthe.2016.10.005","pmid":1,"publication_status":"published","date_updated":"2025-09-18T10:41:35Z","volume":25,"type":"journal_article","publication_identifier":{"issn":["1525-0016"]},"file_date_updated":"2020-07-14T12:47:56Z"}]